UnitedHealth price target lowered to $534 from $551 at Barclays

Barclays lowered the firm’s price target on UnitedHealth to $534 from $551 and keeps an Overweight rating on the shares. The analyst revised estimates following a “bearish” 2025 final rate notice for Medicare Advantage. However, the firm senses a “growing investor appetite to take advantage of the current turmoil” over the next 6-9 months and believes that UnitedHealth is best positioned to outperform over the near- and intermediate-term.